Увійти

Готові списки джерел за темами / Novartis Campus / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Novartis Campus.

Статті в журналах з теми "Novartis Campus"

Автор: Grafiati

Опубліковано: 25 липня 2024

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-33 статей у журналах для дослідження на тему "Novartis Campus".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Latagliata, Roberto, Isabella Capodanno, Maria Cristina Miggiano, et al. "Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study." Blood 138, Supplement 1 (2021): 3617. http://dx.doi.org/10.1182/blood-2021-151538.

Повний текст джерела

Анотація:

Abstract Introduction Treatment of chronic phase (CP) chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) proved to be almost equally effective in young and elderly patients. Three TKIs, imatinib (IM), dasatinib (DAS) and nilotinib (NIL), are approved for frontline therapy in Italy. Choice of frontline TKI is based on a combined evaluation of patient's characteristics and expectations, with age usually playing a prominent role. However, to date, few data are available on patterns of TKI selection in very elderly patients. Aim To analyse the use of frontline TKI therapy in a l

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Chiaretti, Sabina, Massimiliano Bonifacio, Roberta Agrippino, et al. "ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report." Blood 138, Supplement 1 (2021): 216. http://dx.doi.org/10.1182/blood-2021-150958.

Повний текст джерела

Анотація:

Abstract Introduction. The recent spread of the COVID-19 infection has represented an important challenge in the management of acute lymphoblastic leukemia (ALL) patients. Aims and methods. To investigate the incidence, features, source of contagion and outcome of patients with ALL who developed a COVID-19 infection, a survey was conducted among 34 hematology centers throughout Italy within the Campus ALL network. The period covered by the survey spanned from February 2020 to April 2021 and included 756 adult ALL patients actively followed during this time period. Results. Sixty-three of the 7

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Gugliotta, Gabriele, Mario Annunziata, Isabella Capodanno, et al. "Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study." Blood 136, Supplement 1 (2020): 45–46. http://dx.doi.org/10.1182/blood-2020-141077.

Повний текст джерела

Анотація:

INTRODUCTION: Frontline therapy with second generation (2G) tyrosine-kinase inhibitors (TKIs) in chronic phase (CP) chronic myeloid leukemia (CML) patients demonstrated higher efficacy as compared to imatinib, with less patients experiencing treatment failure and progression to advanced disease. However, limited information are currently available on the management and outcome of those CML pts not achieving an optimal response to first-line treatment with a 2G-TKI. AIM: To describe the clinical outcome of CP CML patients without an optimal response to a frontline 2G-TKI that switched to altern

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Tiribelli, Mario, Isabella Capodanno, Maria Cristina Miggiano, et al. "Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study." Blood 138, Supplement 1 (2021): 1487. http://dx.doi.org/10.1182/blood-2021-149780.

Повний текст джерела

Анотація:

Abstract Background Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the first months of therapy are crucial, as optimal response is defined as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year. Methods To evaluate achievement of early molecular response (MR) and incidence of events leading to a TKI change during the 1st year of therapy, we retrospectively studied 1650 CP-CML patients diagnosed from 2012 and 2019 at 31 Hematology Centres a

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Zoller, Frank A., and Roman Boutellier. "Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus." Drug Discovery Today 18, no. 7-8 (2013): 318–22. http://dx.doi.org/10.1016/j.drudis.2012.12.012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Sciumè, Mariarita, Cristina Papayannidis, Antonio Curti, et al. "Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study." Blood 138, Supplement 1 (2021): 3408. http://dx.doi.org/10.1182/blood-2021-147325.

Повний текст джерела

Анотація:

Abstract Blinatumomab (Blina) and inotuzumab (InO) have improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, many patients (pts) relapse after these treatments and little is known on their outcomes after recurrence and re-treatment with subsequent immunotherapy. We hereby describe the clinical characteristics and outcome of 71 pts with R/R B-ALL treated with both Blina and InO in any sequence - Blina/InO or InO/Blina - at different disease recurrences. At diagnosis, the median age was 34 years (15-64) and the male/female ratio was 1.6. Sixteen pts (22%) we

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Bonifacio, Massimiliano, Chiara Elena, Mariella D'Adda, et al. "Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations." Blood 136, Supplement 1 (2020): 43–44. http://dx.doi.org/10.1182/blood-2020-139826.

Повний текст джерела

Анотація:

Background. The Philadelphia (Ph) chromosome (chr.) is the hallmark of chronic myeloid leukemia (CML) and typically results from the reciprocal translocation t(9;22)(q34;11.2). Complex variant translocations (CVT) involving one or more additional chr. are identified in less than 5% of newly diagnosed CML. There are conflicting reports about the prognostic impact of CVT in the achievement of optimal response to tyrosine kinase inhibitor (TKI), and very few studies addressed the role of frontline treatment with imatinib or second generation (2G)-TKI in patients with CVT. Aims. To assess the resp

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Tiribelli, Mario, Roberto Latagliata, Massimo Breccia, et al. "Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"." Blood 136, Supplement 1 (2020): 35–36. http://dx.doi.org/10.1182/blood-2020-135972.

Повний текст джерела

Анотація:

Introduction : therapy of chronic phase (CP) chronic myeloid leukemia (CML) is based on tyrosine kinase inhibitors (TKIs) in virtually all patients. Three TKIs are approved for first-line therapy in Italy: imatinib and two second-generation (2G) TKIs, dasatinib and nilotinib. Choice of the front-line TKI is based on a combined evaluation of patient's and disease characteristics, age, risk, comorbidities and concomitant medications. Treating physician's preference and, in some cases, economic considerations, particularly after the advent of generic imatinib, may play a role in TKI selection. Ho

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Gentile, Massimo, Fortunato Morabito, Giovanni Del Poeta, et al. "External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study." Blood 134, Supplement_1 (2019): 4308. http://dx.doi.org/10.1182/blood-2019-126702.

Повний текст джерела

Анотація:

Novel therapies targeting BTK (ibrutinib), PI3Kδ (idelalisib) and BCL2 (venetoclax) are active in poor-risk chronic lymphocytic leukemia (CLL) and are widely administered to patients with relapsed/refractory (R/R)-CLL. Given the activity of ibrutinib in high-risk CLL patients, including those with del17p/TP53 mutation or germline IGHV genes, we assumed that this drug could diminish the prognostic utility of the CLL-IPI, because the outcome of patients with high- and very high-risk CLL-IPI scores may improve. Recently, Soumerai et al (Lancet Hematology, 2019) proposed a new risk score for overa

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Downton, Teesha, Emma Karlsen, Katharine Cuff, Euan Walpole, Fiona Simpson, and Elgene Lim. "Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer." Cancer Research 83, no. 5_Supplement (2023): OT2–10–05—OT2–10–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-10-05.

Повний текст джерела

Анотація:

Abstract HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer Authors Teesha Downton1,2, Emma Karlsen1, Katharine Cuff3,4, Euan Walpole3,4, Fiona Simpson3,4, Elgene Lim1,2. Affiliations 1Garvan Institute of Medical Research, Darlinghurst NSW, Australia; 2School of Clinical Medicine, St Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales Sydney, Australia; 3Diamantina Institute, University of Queensland

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Downton, Teesha, Davendra Segara, Andrew Ong, et al. "Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer." Cancer Research 83, no. 5_Supplement (2023): OT2–01–10—OT2–01–10. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-01-10.

Повний текст джерела

Анотація:

Abstract WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer Authors Teesha Downton1,2,3, Davendra Segara3, Andrew Ong4, Janne Bingham5, Emma-Kate Carson4, Julia Chen1,2,3, Kate Middleton3, Geoffrey Lindeman6, Andrew Parker3, Elgene Lim1,2,3. Affiliations 1Garvan Institute of Medical Research, Darlinghurst NSW, Australia; 2School of Clinical Medicine, St Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales Sydney, Australia; 3St Vinc

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Roeker, Lindsey E., Lydia Scarfo, Thomas Chatzikonstantinou, et al. "Worldwide Examination of Patients with CLL Hospitalized for COVID-19." Blood 136, Supplement 1 (2020): 45–49. http://dx.doi.org/10.1182/blood-2020-136408.

Повний текст джерела

Анотація:

Introduction: Patients (pts) with CLL may be at particular risk of severe COVID-19 given advanced age and immune dysregulation. Two large series with limited follow-up have reported outcomes for pts with CLL and COVID-19 (Scarfò, et al. Leukemia 2020; Mato, et al. Blood 2020). To provide maximal clarity on outcomes for pts with CLL and COVID-19, we partnered in a worldwide effort to describe the clinical experience and validate predictors of survival, including potential treatment effects. Methods: This international collaboration represents a partnership between investigators at 141 centers.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Giryes, S., K. Dolnikov, A. Balbir-Gurman, D. Militianu, N. Puchkov, and Y. Braun-Moscovici. "AB1028 A SINGLE-CENTER EXPERIENCE WITH TRANSIENT OSTEOPOROSIS – PATIENT CHARACTERISTIC AND APPROACH TO THERAPY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1806.1–1807. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6032.

Повний текст джерела

Анотація:

Background:Transient osteoporosis (TOP) or transient bone marrow edema syndrome is an enigmatic condition of unknown etiology first described in pregnant women. Though usually self limited, TOP causes pain and debilitation and predisposes the patient to avascular necrosis or fractures. The course can be protracted and patient may suffer relapses. Diagnostic method of choice is magnetic resonance imaging (MRI). Based on small case series and expert opinion, several therapeutic approaches have been proposed to hasten the recovery, including bisphosphonates, calcitonin, teriparatide. However, the

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Visentin, Andrea, Francesca Romana Mauro, Daniela Pietrasanta, et al. "Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus." Blood 136, Supplement 1 (2020): 30–31. http://dx.doi.org/10.1182/blood-2020-136883.

Повний текст джерела

Анотація:

INTRODUCTION. Kinase inhibitors and glycoengineered monoclonal antibody, such as obinutuzumab (G), have significantly changed the treatment landscape of chronic lymphocytic leukemia (CLL). Both like the BTK inhibitor ibrutinib (IB) and obinutuzumab plus chlorambucil (G-CHL) are approved as first line therapy in CLL patients unfit for a fludarabine-base treatment. While IB has proved to be superior to bendamustine-rituximab in a phase 3 trial and an ongoing retrospective ERIC study, no head-to-head comparison has been done for IB vs G-CHL in a real-world evidence study. The aim of this study wa

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Kleinert, S., P. Rapp, F. Schuch, et al. "AB0494 COGNITIVE IMPAIRMENT IN AXIAL SPONDYLOARTHRITIS?" Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1274–75. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1353.

Повний текст джерела

Анотація:

Background:There is some evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis(2). However, little is known regarding a possible disease-related impairment of cognitive abilities in axial spondyloarthritis (axSpA).Objectives:To evaluate patients with axSpA regarding cognitive impairments.Methods:Patients with axSpA attending two rheumatology practices were routinely evaluated by rheumatologists and underwent a computer-based memory and attention test (MAT) (3, 4) with subscale scores ranging from 0 (worst) to 15 (best). The results of short-term memory and

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Vitrano, Angela, Giuseppina Calvaruso, Eliana Lai, et al. "Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia." Blood 126, no. 23 (2015): 2141. http://dx.doi.org/10.1182/blood.v126.23.2141.2141.

Повний текст джерела

Анотація:

Abstract Introduction. In the last few decades, the life expectancy of Thalassemia Major (TM) patients has progressively been increasing. The improvement can be due to several factors, including introduction of chelation treatment (Deferoxamine 1965, Deferiprone 1987, Deferasirox 2006), screening of blood for the most common viral agents, aggressive treatment of infection and improved treatment of cardiac complications. However, no comparative survival curves between TM versus Thalassemia Intermedia (TI) have been so far reported. Moreover, no data on life expectancy, after introduction of che

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Aumann, Shlomzion, Uria Tsubary, Sarah Israel, et al. "COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic." Blood 138, Supplement 1 (2021): 4088. http://dx.doi.org/10.1182/blood-2021-148512.

Повний текст джерела

Анотація:

Abstract Previous studies and meta-analyses addressing COVID-19 in patients with hematological malignancies (HM) have reported dramatically high mortality rates of up to 34% [Vigenthira 2020, Garcia-Suarez 2020, Sharafeldin 2021]. These studies, however, were strongly biased towards hospitalized patients, and poorly represented patients who experienced a milder course of COVID-19, not requiring hospitalization. Jerusalem and its metropolitan area, comprising of over 1.3 million inhabitants, was the epicenter of Israel's COVID-19 crisis, with over 200,000 cases. Hadassah Medical Center, one of

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Combe, B., A. Kivitz, Y. Tanaka, et al. "THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 320–21. http://dx.doi.org/10.1136/annrheumdis-2020-eular.276.

Повний текст джерела

Анотація:

Background:Filgotinib (FIL) is an oral, potent, selective JAK1 inhibitor. FINCH 1 (NCT02889796) assessed FIL efficacy and safety in patients (pts) with rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR); primary outcome results at week (W)12 and W24 were previously reported.1Objectives:To present FINCH 1 W52 results.Methods:This global, phase 3, double-blind, active- and placebo (PBO)-controlled study randomised MTX-IR pts with active RA on a background of stable MTX 3:3:2:3 to oral FIL 200 mg or FIL 100 mg once daily, subcutaneous adalimumab (ADA) 40 mg every 2W, or P

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Seror, R., G. Baron, M. Camus, et al. "OP0286 DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJÖGREN’S SYNDROME." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 189.2–190. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2583.

Повний текст джерела

Анотація:

BackgroundToday, there are still no DMARDs licensed for primary Sjögren Syndrome (pSS) patients. Among the explanations, are the limitations of current outcome measures used as primary endpoints: e.g; high placebo response rate, evaluation of either symptoms or systemic activity, and important features not being assessed. The NECESSITY consortium (https://www.necessity-h2020.eu/), including pSS experts from academia, pharmaceutical industry and patient groups formed to develop a new composite responder index, the Sjögren’s Tool for Assessing Response (STAR) that solve the issues of current out

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Tuttle, J., E. Drescher, J. A. Simon-Campos, et al. "POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 397.2–397. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3582.

Повний текст джерела

Анотація:

BackgroundPeresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1, a checkpoint inhibitory receptor, could stimulate physiological immune inhibitory pathways to restore immune homeostasis; this represents a novel approach to treating patients with autoimmune or autoinflammatory diseases.ObjectivesThe objective of this study was to evaluate efficacy and safety of peresolimab in adult participants with moderate-to-severe rheumatoid arthritis (RA).MethodsA Phase 2a, placebo-cont

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Blanco Cáceres, B. A., Á. Andreu-Suárez, M. Valero, et al. "POS1574 SAPHO SYNDROME, CLINIC CHARACTERISTICS FROM THE SAPHO-SORCOM COHORT." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1163–64. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6386.

Повний текст джерела

Анотація:

BackgroundThe SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare disease (<1/10,000) with multiple cutaneous and musculoskeletal manifestations [1]. The most common dermatological manifestations are palmoplantar pustulosis (PPP) and severe acne (SA). Musculoskeletal manifestations are diverse, including the thoracic wall, spine, temporomandibular joint, and peripheral joints [2]. It is considered as part of spondyloarthropathies, however, no significant relationship with HLA-B27 has been found [3]. For treatment, non-steroidal anti-inflammatory drugs (NSAIDs)

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Lerma, J. J., A. Gracia, A. Perez, et al. "AB0698 REAL CLINICAL PRACTICE IN THE CONTROL OF REPORTED OUTCOMES BY THE PATIENT (PROS) DIAGNOSED WITH PSORIATIC ARTHRITIS AND/OR ANKYLOSING SPONDYLITIS WHO BEGIN TREATMENT WITH SECUKINUMAB. A PROSPECTIVE MULTICENTRIC STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1645.1–1645. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2795.

Повний текст джерела

Анотація:

Background:Objectives:Analyse the effect of secukinumab in terms of the patient´s own variables, specifically: fatigue, sleep, pain and quality of life in patients with psoriatic arthritis or spondyloarthritis.Methods:A multicentric longtitudinal observational prospective study was carried out at 6 months in patients who begin treatment with secukinumab. At the start and after 6 months the following data was collected on the outcome: pain through an visual analogue scale (VAS), fatigue using the FACIT-fatigue scale, sleeping problems using the insomnia severity index (ISI) and quality of life

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Becker-Capeller, D., and S. Kapsimalakou. "AB0799 Anatomical abnormalities of the lower lumbar spine do not change the course of non-radiological axial spondyloarthritis." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1526.2–1526. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1653.

Повний текст джерела

Анотація:

BackgroundDiagnosing early spondyloarthritis (SpA) is crucial for effective therapeutic intervention. Magnetic resonance imaging (MRI) helps us to diagnose non-radiographic SpA (nr-ax SpA) in an early stage according to the criteria of the imaging arm of the Assessment of Spondyloarthritis International Society (ASAS) classification. Diagnosis of sacroiliitis using MRI has limitations because of the lack of specificity and sensitivity. Several differential diagnoses are well known and should be considered1. In our daily practice, anomalies of the lower lumbar spine and the sacrum, such as spon

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Camus, Vincent, Alina Berriolo-Riedinger, Justine Lequesne, et al. "R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers." Blood 136, Supplement 1 (2020): 20–21. http://dx.doi.org/10.1182/blood-2020-136600.

Повний текст джерела

Анотація:

Introduction: Primary mediastinal B cell lymphoma (PMBL) is clinically and biologically distinct from the other subtypes of diffuse large B cell lymphoma (DLBCL), typically affecting young female patients (pts) with a bulky mediastinal mass. Standard treatment (TRT) is a combination of anti-CD20 antibody (Ab) and anthracycline-based chemotherapy. We aimed to compare patients' outcomes after CHOP delivered every 21 days (CHOP21) or 14 days (CHOP14) or ACVBP combined with anti-CD20 Ab in real life. Methods: All Pts treated in LYSA centers were eligible in this retrospective analysis. Inclusion c

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Atienza-Mateo, B., A. Serrano-Combarro, M. Martin Lopez, et al. "POS0864 EFFECTIVENESS OF ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 50 PATIENTS IN CLINICAL PRACTICE." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 737.2–737. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5665.

Повний текст джерела

Анотація:

BackgroundInterstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD[1-4]. However, progression of ILD despite its use is not uncommon. A subgroup analysis of the INBUILD trial has shown a slower decline in forced vital capacity (FVC) in patients with progressive fibrosing autoimmune disease-related ILDs with the antifibrotic nintedanib (NINTE)[5].ObjectivesA) To assess the efficacy of antifibrotic drugs, NINTE and pirfenidone (PIRFE), in Spanish RA-ILD patients with

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Bertram, Dominik, Tobias Chilla, and Marc Pfister. "Large urban development projects in company towns. The cases of Erlangen (Siemens) and Basel (Novartis)." Raumforschung und Raumordnung | Spatial Research and Planning, July 3, 2025. https://doi.org/10.14512/rur.2967.

Повний текст джерела

Анотація:

The literature on large-scale urban development projects often primarily addresses drastic failures and their underlying causes. Recently, however, success factors have also received increasing attention. From both perspectives, management approaches, participation logics and political strategies are prominent topics in this context. However, the symbolic dimension of large urban development projects is rarely considered. This is somewhat surprising, as symbolic meaning is considered key to urban development in many contexts. We explore this dimension with two cases of urban entrepreneurial de

Стилі APA, Harvard, Vancouver, ISO та ін.

27

"RE(ACT)2014Rare Diseases. 2nd International Congress on Research of Rare and Orphan Diseases. 5th to 8th March 2014, Gehry Building, Novartis Campus, Basel: Abstracts." Molecular Syndromology 5, no. 2 (2014): 87–99. http://dx.doi.org/10.1159/000358504.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

"Real-World Gait Detection Using a Wrist-Worn Inertial Sensor: Validation Study." JMIR Formative Research, May 13, 2024. https://doi.org/10.2196/50035.

Повний текст джерела

Анотація:

Felix Kluge <sup>1</sup>, PhD;  Yonatan E Brand <sup>2</sup>, MSc;  M Encarna Micó-Amigo <sup>3</sup>, PhD;  Stefano Bertuletti <sup>4</sup>, PhD;  Ilaria D'Ascanio <sup>5</sup>, MSc;  Eran Gazit <sup>6</sup>, MSc;  Tecla Bonci <sup>7</sup>, PhD;  Cameron Kirk <sup>3</sup>, PhD;  Arne Küderle <sup>8</sup>, MSc;  Luca Palmerini <sup>5, 9</sup>, PhD;  Anisoara Paraschiv-Ionescu <sup>10</sup>, PhD;  Francesca Salis <s

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Walker, David, Alan Kivitz, Yoshiya Tanaka, et al. "P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data." Rheumatology 60, Supplement_1 (2021). http://dx.doi.org/10.1093/rheumatology/keab247.129.

Повний текст джерела

Анотація:

Abstract Background/Aims Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor. FINCH 1 (NCT02889796) assessed FIL efficacy, safety and patient reported outcome (PRO) data in patients (pts) with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX-IR). We report data through week 52 (W52) of the FINCH 1 study. Primary outcome results at week (W)12 and W24 were previously reported. Methods This global, phase 3, double-blind, active- and placebo (PBO)-controlled study randomised MTX-IR pts with active RA on a background of stable MTX 3:3:2:3 to oral

Стилі APA, Harvard, Vancouver, ISO та ін.

30

KRUTKYTE, GABIJA, ARNA MARIE CATHERINE GOERG, CHRISTIAN A. GROB, et al. "268-OR: Perioperative Fully Closed-Loop vs. Standard Insulin Delivery in Adults Undergoing Major Abdominal Surgery—A Two-Center Randomized Controlled Trial." Diabetes 73, Supplement_1 (2024). http://dx.doi.org/10.2337/db24-268-or.

Повний текст джерела

Анотація:

Introduction: Major abdominal surgery predisposes to hyperglycemia due to metabolic stress, inflammation, perioperative nutrition support and medication. The aim of the study was to assess the efficacy of fully closed-loop (FCL) versus usual care (UC) insulin delivery for glycemic management in major abdominal surgery patients. Methods: In this randomized controlled trial (NCT05392452) we compared perioperative use of the CamAPS HX FCL system (Dexcom G6, YspoPump, SC faster insulin aspart) with UC insulin treatment from admission until hospital discharge (max 20 days) at two tertiary hospitals

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Campos, Jesus Abraham Simón, Douglas Arbetter, Hugh Montgomery, et al. "1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial." Open Forum Infectious Diseases 9, Supplement_2 (2022). http://dx.doi.org/10.1093/ofid/ofac492.1545.

Повний текст джерела

Анотація:

Abstract Background Outpatient treatment with SARS-CoV-2–neutralizing antibody combination AZD7442 (tixagevimab/cilgavimab) in adults with mild to moderate COVID-19 significantly reduced progression to severe disease or death through Day 29 and was well-tolerated in the Phase 3 TACKLE study (NCT04723394). We report a post hoc analysis of the impact of AZD7442 in reducing self-reported COVID-19 symptom severity and time to symptom resolution through Day 29 in TACKLE. Methods In TACKLE, non-hospitalized adults with mild to moderate COVID-19 were randomized 1:1 and dosed ≤7 days from symptom onse

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Richard Hobbs, F. D., Hugh Montgomery, Francisco Padilla, et al. "1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial." Open Forum Infectious Diseases 9, Supplement_2 (2022). http://dx.doi.org/10.1093/ofid/ofac492.1551.

Повний текст джерела

Анотація:

Abstract Background Outpatient treatment with SARS-CoV-2–neutralizing antibody combination AZD7442 (tixagevimab/cilgavimab) in adults with mild to moderate COVID-19 significantly reduced progression to severe disease or death through Day 29 and was well-tolerated in the Phase 3 TACKLE study primary analysis (NCT04723394). AZD7442 administered earlier in the disease course leads to more favorable outcomes and has the potential to prevent COVID-19 hospitalizations and reduce hospital burden. We report key secondary efficacy results with longer-term safety data from TACKLE over 6 months. Methods

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Richard Hobbs, F. D., Hugh Montgomery, Francisco Padilla, et al. "529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study." Open Forum Infectious Diseases 10, Supplement_2 (2023). http://dx.doi.org/10.1093/ofid/ofad500.598.

Повний текст джерела

Анотація:

Abstract Background In the TACKLE phase 3 outpatient treatment study, 600-mg AZD7442 (tixagevimab/cilgavimab) in adults with mild to moderate COVID-19 significantly reduced progression to severe disease or death over 29 days and was well-tolerated at primary analysis. Here, we report final safety findings from TACKLE. Methods In TACKLE (NCT04723394), non-hospitalized adults with mild to moderate COVID-19 were randomized 1:1 and dosed ≤7 days from symptom onset with 600-mg AZD7442 (N=452) or placebo (N=451). Results are reported from the January 22, 2023 final data cut-off. The primary safety e

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!